ImmPACT Bio Revenue and Competitors

0, CA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ImmPACT Bio's estimated annual revenue is currently $25.1M per year.(i)
  • ImmPACT Bio's estimated revenue per employee is $155,000

Employee Data

  • ImmPACT Bio has 162 Employees.(i)
  • ImmPACT Bio grew their employee count by 35% last year.

ImmPACT Bio's People

NameTitleEmail/Phone
1
Chief Technology OfficerReveal Email/Phone
2
VP Human ResourcesReveal Email/Phone
3
VP FinanceReveal Email/Phone
4
VPReveal Email/Phone
5
Associate Director, Process DevelopmentReveal Email/Phone
6
Director, QA OperationsReveal Email/Phone
7
Associate Director, ITReveal Email/Phone
8
Senior Director Regulatory AffairsReveal Email/Phone
9
Medical DirectorReveal Email/Phone
10
Director, External Manufacturing & CMC LeadReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is ImmPACT Bio?

ImmPACT Bio is dedicated to the discovery of transformative CAR-T cell therapies for cancer patients who have exhausted their treatment options. Our technology is designed to precisely distinguish cancerous cells from normal cells; thereby eliminating tumors without damaging normal tissues. Our goal is to eradicate tumors without generating the severe side effects that are difficult, sometimes impossible, for cancer patients to endure. The company was founded in 2017 in the FuturRx incubator (Israel). In 2019, ImmPACT Bio was incorporated in the US and R&D operations were established in Camarillo, CA. In 2021 ImmPACT Bio merged with Kalthera.

keywords:N/A

N/A

Total Funding

162

Number of Employees

$25.1M

Revenue (est)

35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$204.3M4951%$40M